Martin Murphy and Freddie Dear explain why Syncona has expanded Quell’s financing to support the additional pipeline programmes, how they have worked with the Quell team, and their ambition for the company to become a global leader in treating liver transplantation, autoimmune and inflammatory diseases.
- About us
- Our people
- Portfolio
- Sustainability
- News and insights
- Investors
- Contact